Canaccord raised the firm’s price target on Verona Pharma (VRNA) to $72 from $44 and keeps a Buy rating on the shares. The firm believes the ...

Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for ...

Ohtuvayre™is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients ...

For further information please contact: Verona P Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3 Through October more than 2,200 unique ...

Verona Pharma PLC (NASDAQ:VRNA) shares have reached an all-time high, touching a price level of $62.09. According to ...

Verona Pharma (VRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on the ...

Verona Pharma reported a total of $36 million in net revenue for the fourth quarter of 2024, solely attributed to sales of Ohtuvayre (ensifentrine), its FDA-approved treatment for chronic ...

Verona Pharma stock hit a record high Thursday — running up 19% over the past four days — on continued enthusiasm for its COPD treatment, Ohtuvayre. Please watch the video at Investors.com ...

and now Verona has revealed the drug made approximately $36 million in the final three months of 2024, off more than 16,000 prescriptions. Chief executive David Zaccardelli said Ohtuvayre was off ...

Moreover, Verona Pharma has partnered with Ritedose for the development and manufacturing of Ohtuvayre.